These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 32673828)
21. Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2 Liu Z; Jiang L; Li Y; Xie B; Xie J; Wang Z; Zhou X; Jiang H; Fang Y; Pan H; Han W EBioMedicine; 2019 Apr; 42():326-339. PubMed ID: 30879923 [TBL] [Abstract][Full Text] [Related]
22. Crizotinib in Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808 [TBL] [Abstract][Full Text] [Related]
23. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
25. Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients. Xin S; Fang W; Li J; Li D; Wang C; Huang Q; Huang M; Zhuang W; Wang X; Chen L J Cancer Res Clin Oncol; 2021 Mar; 147(3):725-737. PubMed ID: 33387041 [TBL] [Abstract][Full Text] [Related]
26. Crizotinib for Tacar SY; Yilmaz M; Oz B; Tural D Tumori; 2022 Jun; 108(3):258-262. PubMed ID: 33849345 [TBL] [Abstract][Full Text] [Related]
27. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. Lin JJ; Chin E; Yeap BY; Ferris LA; Kamesan V; Lennes IT; Sequist LV; Heist RS; Mino-Kenudson M; Gainor JF; Shaw AT J Thorac Oncol; 2019 Jan; 14(1):135-140. PubMed ID: 30205166 [TBL] [Abstract][Full Text] [Related]
28. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442 [TBL] [Abstract][Full Text] [Related]
29. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593 [TBL] [Abstract][Full Text] [Related]
30. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With Hur JY; Ku BM; Shim JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ In Vivo; 2020; 34(3):1399-1406. PubMed ID: 32354937 [TBL] [Abstract][Full Text] [Related]
31. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363 [TBL] [Abstract][Full Text] [Related]
32. Multikinase Inhibitor Crizotinib Is Active in Cancer Discov; 2020 Mar; 10(3):337. PubMed ID: 31980568 [TBL] [Abstract][Full Text] [Related]
33. MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma. Miao YL; Xu QQ Lung Cancer; 2019 Apr; 130():84-86. PubMed ID: 30885356 [TBL] [Abstract][Full Text] [Related]
34. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Loong HH; Mok K; Leung LK; Mok TS Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678 [TBL] [Abstract][Full Text] [Related]
35. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999 [TBL] [Abstract][Full Text] [Related]
36. Going After Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157 [TBL] [Abstract][Full Text] [Related]
37. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835 [TBL] [Abstract][Full Text] [Related]
38. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. Wu YL; Yang JC; Kim DW; Lu S; Zhou J; Seto T; Yang JJ; Yamamoto N; Ahn MJ; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner KD; Goto K J Clin Oncol; 2018 May; 36(14):1405-1411. PubMed ID: 29596029 [TBL] [Abstract][Full Text] [Related]
39. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. Wiesweg M; Herold T; Metzenmacher M; Eberhardt WE; Reis H; Darwiche K; Aigner C; Stuschke M; Herrmann K; Nensa F; Schildhaus HU; Schuler M Lung Cancer; 2020 Jan; 139():165-168. PubMed ID: 31809977 [TBL] [Abstract][Full Text] [Related]
40. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]